[O-35] Oral Session 35

[O-35-2] FIREFISH Parts 1 and 2: Safety and efficacy of risdiplam in Type 1 spinal muscular atrophy

^○Yasuhiro Takeshima¹, Masson Riccardo², Mazurkiewiczbeldzinska Maria³, Rose Kristy⁴, Servais Laurent⁵, Xiong Hui⁶, Zanoteli Edmar⁷, El-khairi Muna⁸, Gerber Marianne⁹, Gorni Ksenija⁹, Kletzl Heidemarie⁹, Dodman Angela⁹, Gaki Eleni⁸, Darras Basil T¹⁰ (1.Department of Paeditrics, Hyogo College of Medicine, Japan, 2.Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, 3.Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 4.Department of Developmental Neurology, Medical University of Gdansk, Gdansk, Poland, 5.Paediatric Gait Analysis Service of New South Wales, The Children's Hospital at Westmead, Sydney, Australia, 6.I-Motion - Hopital Armand Trousseau, Paris, France, 7.Department of Pediatrics, Peking University First Hospital, Beijing, China, 8.Department of Neurology, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil;, 9.Roche Products Ltd, Welwyn Garden City, UK, 10.F. Hoffmann-La Roche Ltd, Basel, Switzerland)